COVID-19 vaccine maker Moderna is looking for a lift from Uber—a collaboration lift, that is. The two companies say they're planning to work together to promote vaccine confidence and ease access to coronavirus shots.Early ideas include promoting vaccine safety on the Uber network and through in-app messages as well as incorporating Uber rides into the vaccination scheduling process.While those details are still in the works, the appeal of Uber as a part......

Ascentage Pharma, an around the world engaged, clinical-stage biotechnology organization occupied with creating novel treatments for malignant growths, persistent hepatitis B (CHB), and age-related illnesses, introduced at the J.P. Morgan 39th Annual Healthcare Conference (a virtual occasion) at night of January 13, Beijing Time. During the introduction, Dr. Dajun Yang, Chairman and CEO of Ascentage Pharma, furnished business refreshes with an attention on the organization's worldwide R&......

Newly emerged variants of the novel coronavirus have sparked a key question: Will existing COVID-19 vaccines be less effective against them? But scientists have preliminary data showing that may not be the case, at least for Pfizer and BioNTech’s shot.Researchers from the University of Texas and Pfizer found that, in lab dishes, the vaccine was able to neutralize an engineered version of a variant, which bears an N501Y mutation in its spike protein. The finding was publishe......

Pushing for another endorsement for SGLT2 prescription Farxiga in persistent kidney illness (CKD), AstraZeneca a year ago posted amazing information in its critical preliminary. Presently, the FDA has acknowledged its CKD application and granted a need survey, setting up a choice for the subsequent quarter—and putting Farxiga significantly farther in front of its future adversaries.In that preliminary, named Dapa-CKD, AZ's Farxiga in addition to standard of care cut the......

Sebela Pharmaceuticals® today announced that SUTAB® (sodium sulfate, magnesium sulfate, and potassium chloride) tablets, the first tablet colonoscopy preparation to receive approval from the U.S. Food and Drug Administration (FDA) in over 10 years, is now available in the United States.SUTAB is a sulfate-based tablet colonoscopy preparation that is taken orally in a split-dose administration starting the evening before a colonoscopy. The tablets offer a safe and effective alterna......